NYSEHealth CarePharmaceutical PreparationsCHICAGO, IL

MAIA Biotechnology, Inc. MAIA

Ask your AI

Estimated market cap $61.75M61.75M shares, shares as of Nov 9, 2026CIK 1878313

Insider trades, 12 mo

27 buys · 0 sells

$986.0K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

10.8% of shares · 4 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in MAIA Biotechnology, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 9, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in MAIA Biotechnology, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

27 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Sep 14, 2026. Insiders have two business days to file.

Recent insider trades

Vlad Vitoc Chief Executive Officer, Director, 10% owner	Sep 14 Form 4 ↗	Buy	+$100.0K 73,000 sh @ $1.37	-27.2%
Ramiro Guerrero Director	Sep 10 Form 4 ↗	Buy	+$49.6K 37,595 sh @ $1.32	-23.2%
Ramiro Guerrero Director	Aug 28 Form 4 ↗	Buy	+$62.9K 46,620 sh @ $1.35	-22.9%
Ramiro Guerrero Director	Aug 27 Form 4 ↗	Buy	+$108.8K 78,239 sh @ $1.39	-25.4%
Ramiro Guerrero Director	Aug 26 Form 4 ↗	Buy	+$12.4K 8,931 sh @ $1.39	-26.5%

All MAIA insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

6.66M shares

27 funds report MAIA. Values checked against market prices.

Funds own 22% of shares (Q2 2026)

36 funds hold the stock.

Q3 2026: 11% · 5,560 of ~8,900 funds reported so far

Q2 20256.9%
Q3 20256.4%
Q4 20256.8%
Q1 202622%
Q2 202622%
Q3 2026 (so far)11%

Q3 2026. 8 new, 4 added to, 5 trimmed, 17 exited since Q2 2026.

Top 13F holders
#
1	Vanguard Capital Management LLC 13F ↗	2.41M	$2.8M	unchanged
2	Centric Wealth Management 13F ↗	1.17M	$1.3M	+46.5%
3	Geode Capital Management, LLC 13F ↗	584,401	$689.8K	+15.9%
4	Bleichroeder LP 13F ↗	500,000	$590.0K	unchanged
5	Renaissance Technologies LLC 13F ↗	399,100	$470.9K	-4.0%
6	BlackRock, Inc. 13F ↗	394,772	$465.8K	-2.0%
7	Vanguard Fiduciary Trust Co 13F ↗	336,688	$397.3K	unchanged
8	State Street Corp 13F ↗	218,850	$258.2K	+8.5%
9	Bleakley Financial Group, LLC 13F ↗	181,623	$214.3K	unchanged
10	Morgan Stanley 13F ↗	104,017	$122.7K	unchanged

Download CSV Every fund that holds MAIA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What MAIA Biotechnology, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What MAIA Biotechnology, Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at MAIA Biotechnology, Inc.

3 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to MAIA Biotechnology, Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at MAIA Biotechnology, Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	1	1	1
2025 Q1	0	0	0
2025 Q2	0	0	0
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	3	4	3

Most common job titles at MAIA Biotechnology, Inc.

Scientist III, Upstream Process Development	2	—
Scientist I, Upstream Process Development	1	—

All MAIA applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2022	9	—	231,313	$763.0K
Q4 2022	6	-3	297,126	$1.0M
Q1 2023	6	0	71,531	$246.7K
Q2 2023	12	+6	321,938	$709.1K
Q3 2023	14	+2	318,305	$699.6K
Q4 2023	22	+8	808,483	$963.8K
Q1 2024	20	-2	681,140	$1.5M
Q2 2024	21	+1	1.79M	$6.1M
Q3 2024	17	-4	1.47M	$4.1M
Q4 2024	20	+3	1.39M	$2.8M
Q1 2025	20	0	1.48M	$2.3M
Q2 2025	20	0	2.28M	$4.0M
Q3 2025	19	-1	2.37M	$3.5M
Q4 2025	26	+7	2.52M	$4.1M
Q1 2026	33	+7	13.15M	$18.4M
Q2 2026	36	+3	13.52M	$19.4M
Q3 2026	27	-9	6.66M	$7.8M

Each point is a quarter-end, from Q3 2022 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (552641102). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2022) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes3 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history3 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: MAIA Biotechnology, Inc.
Address: 444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL 60606
Phone: 312-416-8592
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: MAIA (NYSE)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.00−$0.01 (−0.99%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.00 · High $1.18Nov 13, 2026

Aug 13, 2026Low $1.00 · High $1.41Nov 13, 2026

Nov 13, 2025Low $0.871 · High $2.95Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.